Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer
Interventional
Phase 2
Fudan university shanghai cancer center, Deparment of gynecologic oncology
Sponsor: Fudan University
Last Updated: August 14, 2024 Notice- Information is sourced from public registries and may not reflect real-time changes at the local site.
This study aims to investigate the safety and efficacy of combination therapy of Fluzoparib combined With Dalpiciclib for platinum-resistant recurrent ovarian cancer through a single-center, prospective, single-arm, phase II clinical trial, to improve the overall treatment level and prognosis of platinum-resistant ovarian cancer.